List view / Grid view
In this exclusive interview with Young Kwon, CEO of Alchemab, we discuss new platforms that are revolutionising how researchers identify naturally occurring antibodies in resilient individuals, opening up new possibilities for the development of disease-modifying therapies.
During embryogenesis, organs must achieve a precise cell count and functional structure. Embryos efficiently manage multiple tasks—growth, shaping, and architecture establishment. Despite extensive research on embryonic development, the intricate coordination of these tasks in both space and time remains incompletely understood.
Cutting-edge research conducted by experts at Michigan Medicine, the Children’s Hospital of Philadelphia, and Penn Medicine is revolutionising the approach to treating blood disorders like sickle cell anaemia through innovative gene therapy methods.
Researchers have made a significant breakthrough in the field of ageing research, uncovering a key driver of chronic inflammation that accelerates the ageing process.
The launch of our new series, "Beyond the Lab," promises to deliver high-level insights commissioned exclusively by Drug Target Review magazine. Our inaugural report is an exploration of the remarkable advancements in cell and gene therapy that are revolutionising the field of drug discovery.
14 July 2023 | By BPS Bioscience
Watch this webinar to get an overview of the CAR-T workflow and learn about the latest CAR-T research enabling tools that can accelerate your discovery.
Japanese study has identified three previously unknown membrane proteins in ovarian cancer, using a new detection method consisting of nanotechnology and imaging techniques.
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
Dr John Maher discusses the challenges associated with developing chimeric antigen receptor (CAR) T-cell therapy for solid tumours.
Dr David Baram from gene therapy company EmendoBio provides a snapshot of the history of therapeutic genetic engineering.
Come and join us for our monthly series highlighting Women in STEM. We are excited to present the latest edition for June, featuring an exclusive interview with Dr Jo Brewer, Chief Scientific Officer at Adaptimmune. With a remarkable 15-years of experience in cell therapy, Jo's passion for cells has been…
A new Drug Target Review issue is now ready to download! This issue features articles on cell and gene therapy, imaging and screening.
Insilico Medicine has announced the nomination of ISM6331 as a potential best-in-class pan-TEAD inhibitor for the treatment of advanced solid tumours.
This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, explores research on T-cell therapy for cancer, which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.
Tune into this podcast to hear experts discussing the current landscape of adoptive cell therapies!
